Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Despite the continuing difficult and unstable global operating environment, Clorox managed an all-around beat in the last quarterly results.</li><li>The fact remains that Clorox is already facing a number of macro challenges and future quarters may not be showing such a positive performance.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Despite the continuing difficult and unstable global operating environment, Clorox managed an all-around beat in the last quarterly results.The fact remains that Clorox is already facing a number of macro challenges and future quarters may not be showing such a positive performance.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Clorox Inc: New Eco-Friendly Product Launches & Other Drivers

<ul><li>Clorox Co has navigated via challenging operating conditions and it failed to meet Wall Street expectations in terms of revenues.</li><li>As a part of the company’s IGNITE strategy, it has announced a streamlined operating model for creating a faster, simpler company.</li><li>One of the best ways to expand margins for Clorox has been its direct-to-consumer strategy which is gradually paying off.</li></ul>

Clorox Co has navigated via challenging operating conditions and it failed to meet Wall Street expectations in terms of revenues.As a part of the company’s IGNITE strategy, it has announced a streamlined operating model for creating a faster, simpler company.One of the best ways to expand margins for Clorox has been its direct-to-consumer strategy which is gradually paying off.

Clorox Co.: Innovation-Led Growth & Other Drivers

Equity Capital Markets

<ul><li>Like most of its consumer goods peers, Clorox faced significant cost headwinds in a volatile operating environment, but they performed decently well on the factors within their control despite these difficult circumstances.</li><li>This includes restoring supply, serving customers, and moving forward with its consumer-centric innovation pipeline, as well as taking strategic pricing actions and driving cost savings.</li><li>Demand remained strong across Clorox’s portfolio, and the premium associated with its brands over other incumbents and private labels is unquestionable.</li></ul>

Like most of its consumer goods peers, Clorox faced significant cost headwinds in a volatile operating environment, but they performed decently well on the factors within their control despite these difficult circumstances.This includes restoring supply, serving customers, and moving forward with its consumer-centric innovation pipeline, as well as taking strategic pricing actions and driving cost savings.Demand remained strong across Clorox’s portfolio, and the premium associated with its brands over other incumbents and private labels is unquestionable.

The Clorox Co.: Financial & Price Forecasts

Asset Allocation & Fund Positioning, Copley Fund Research

Steven Holden

Asset Allocation & Fund Positioning

Copley Fund Research

Copley Fund Research provide research and data on asset allocation among Global and Emerging Market equity funds.  The analysis details absolute and relative positioning across countries, sectors and industries together with highly granular data on single stock and single fund allocations.  The data is updated monthly with time series going back to January 2011.

Global Research - Analysis of 165 prominent Global equity funds, combined AUM $335bn
GEM Research - Analysis of 127 prominent global EM equity funds, combined AUM $250bn

Asset Allocation - Global and GEM Equity

Cross Asset Strategy

Over 50% of allocations are in the US with the bulk of the remainder split between Japan, China &amp; HK and the major European nations.  The EMEA overweight is comprised mainly of the UK, Netherlands, France and Germany, with active managers running underweights in the US, China &amp; HK, Australia and Japan.UK allocations hover around their lowest levels in history, though managers remain stubbornly overweight compared to the MSCI AC World index.  A total of 62% of managers are overweight the UK at an average +1.88% above benchmark.  Global Value investors are approaching their largest ever overweight in UK stocks of 3.64% above benchmark.Another month, another slump in Japan exposure.  Average weights in Japan stand at an all-time low of 5.06% with 85.5% of funds exposed (another low). <a href="https://www.smartkarma.com/entities/sony-corp" target="_blank" data-smartkarma-citation="entities:563:1" rel="noopener">Sony Corp (6758 JP)</a> and <a href="https://www.smartkarma.com/entities/kddi-corp" target="_blank" data-smartkarma-citation="entities:639:1" rel="noopener">KDDI Corp (9433 JP)</a> are the most widely held stocks, with 23% and 21% of funds holding a position.Tech exposure is at record highs, though this is matched by a record underweight of -0.47%.  Indeed, the percentage of funds who are overweight technology has fallen to below 50% for the first time since the end of 2018, a sign that Global managers are tilting their portfolios away from Tech.German Industrials allocations have hit a 4-year high as more Global investors add exposure to the sector. <a href="https://www.smartkarma.com/entities/deutsche-post-ag" target="_blank" data-smartkarma-citation="entities:21608:1" rel="noopener">Deutsche Post AG (DPW GR)</a> and <a href="https://www.smartkarma.com/entities/siemens-ag" target="_blank" data-smartkarma-citation="entities:21713:1" rel="noopener">Siemens AG (SIE GR)</a> were the key stocks behind the move, with 4.2% and 2.4% of funds adding exposure over the last 6-months.Alibaba has seen closures by some of the larger holders in our analysis, led by American Funds Capital World Fund (-$1.1bn) and New Economy Fund (-$451m).  Though closures have dominated, selected funds have opened exposure during this period of volatility, including Invesco's Global Focus Fund and Liontrust's Global Income Fund.

Over 50% of allocations are in the US with the bulk of the remainder split between Japan, China &amp; HK and the major European nations.  The EMEA overweight is comprised mainly of the UK, Netherlands, France and Germany, with active managers running underweights in the US, China &amp; HK, Australia and Japan.UK allocations hover around their lowest levels in history, though managers remain stubbornly overweight compared to the MSCI AC World index.  A total of 62% of managers are overweight the UK at an average +1.88% above benchmark.  Global Value investors are approaching their largest ever overweight in UK stocks of 3.64% above benchmark.Another month, another slump in Japan exposure.  Average weights in Japan stand at an all-time low of 5.06% with 85.5% of funds exposed (another low). Sony Corp (6758 JP) and KDDI Corp (9433 JP) are the most widely held stocks, with 23% and 21% of funds holding a position.Tech exposure is at record highs, though this is matched by a record underweight of -0.47%.  Indeed, the percentage of funds who are overweight technology has fallen to below 50% for the first time since the end of 2018, a sign that Global managers are tilting their portfolios away from Tech.German Industrials allocations have hit a 4-year high as more Global investors add exposure to the sector. Deutsche Post AG (DPW GR) and Siemens AG (SIE GR) were the key stocks behind the move, with 4.2% and 2.4% of funds adding exposure over the last 6-months.Alibaba has seen closures by some of the larger holders in our analysis, led by American Funds Capital World Fund (-$1.1bn) and New Economy Fund (-$451m).  Though closures have dominated, selected funds have opened exposure during this period of volatility, including Invesco's Global Focus Fund and Liontrust's Global Income Fund.

Global Fund Positioning Update:  Japan Lows, US Highs, UK Value Rotation, Tencent & Alibaba Exit

<ul><li>Clorox's recent result was completely below par and the stock has limited scope for growth in the short term.</li><li>Despite the complexities associated with the pandemic, the company managed to deliver a 9% sales growth for fiscal 2021 on a reported and organic basis, reflecting a positive growth in all four reportable segments.</li><li>Rising raw material prices resulted Clorox’s gross margin declining by 200 basis points mainly in the fourth quarter.</li></ul>

Clorox's recent result was completely below par and the stock has limited scope for growth in the short term.Despite the complexities associated with the pandemic, the company managed to deliver a 9% sales growth for fiscal 2021 on a reported and organic basis, reflecting a positive growth in all four reportable segments.Rising raw material prices resulted Clorox’s gross margin declining by 200 basis points mainly in the fourth quarter.

United States

The Clorox Company produces and markets non-durable consumer products sold primarily through grocery and other retail stores.  The Company's principal products include household cleaning and bleach products, charcoal, cat litter, automotive care products, dressings, and trash bags.  Clorox markets its products in the United States and other countries around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Clorox Company (CLX US)

Clorox Inc: New Eco-Friendly Product Launches & Other Drivers

Despite the continuing difficult and unstable global operating environment, Clorox managed an all-around beat in the last quarterly results. The...

Baptista Research

Clorox Co.: Innovation-Led Growth & Other Drivers

Clorox Co has navigated via challenging operating conditions and it failed to meet Wall Street expectations in terms of revenues. As a part of the...

Baptista Research

The Clorox Co.: Financial & Price Forecasts

Like most of its consumer goods peers, Clorox faced significant cost headwinds in a volatile operating environment, but they performed decently...

Baptista Research

Global Fund Positioning Update: Japan Lows, US Highs, UK Value Rotation, Tencent & Alibaba Exit

A detailed look at investor positioning among 380 active Global strategies, covering the major themes in country, sector and stock exposure.

Steven Holden

Clorox Co - Investment Thesis

Clorox's recent result was completely below par and the stock has limited scope for growth in the short term. Despite the complexities associated...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)